PRIMESECU.NS
Prime Securities Limited
NSEINREQUITY
Financial Services
DELAYED
Last price
278.40
▲ 2.35 (0.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
276.00
Prev close
276.05
Day high
280.95
Day low
274.90
Volume
17.48K
Market cap
$9.44B
P/E (TTM)
209.17
52W range
244.50 – 325.00
Day trading desk
Gap from prior close
-0.23%
Prior close 276.65
VWAP
278.90
-0.18% from price
Relative volume
0.42×
Quiet session
Session range
1.79%
276.00 – 280.95
Position in range
48%
Mid range
ATR (14D)
10.24
3.68% of price
Prior day high
278.80
PDH
Prior day low
274.85
PDL
Bid / ask spread
—
Quote not published
Session volume
16.75K
Avg 40.07K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.80%
-0.6%
1M
+1.37%
-2.0%
3M
-2.28%
-4.7%
6M
+0.16%
-11.7%
YTD
+0.76%
-11.2%
1Y
+4.35%
-15.8%
3Y
+102.18%
+27.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PRIMESECU.NS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
26.79M
Total on file
Fundamentals
Market cap$9.44B
Enterprise value$13.76B
Revenue (TTM)$1.23B
Gross profit$1.10B
EBITDA—
Net income$84.80M
EPS (TTM)$1.33
Free cash flow—
Total cash$46.90M
Total debt$15.10M
Book value / share$91.74
Shares outstanding33.94M
Float31.38M
Short % of float—
Dividend yield0.50%
Beta (5Y)0.21
Valuation & profitability ratios
Trailing P/E209.17
Forward P/E—
PEG ratio—
Price / sales—
Price / book3.03
EV / revenue11.18
EV / EBITDA—
Gross margin89.21%
Operating margin19.18%
Profit margin6.89%
Return on equity—
Return on assets—
Debt / equity0.58
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.28B | $798.00M | $615.10M | $405.40M | — | +60.0% |
| Operating revenue | $1.28B | $798.00M | $615.10M | $405.40M | — | +60.0% |
| Cost of revenue | $788.70M | $370.30M | $328.50M | $227.80M | — | +113.0% |
| Gross profit | $488.10M | $427.70M | $286.60M | $177.60M | — | +14.1% |
| Selling, general & admin | — | $24.30M | $30.40M | $29.70M | $23.40M | — |
| Total operating expense | $208.90M | $89.90M | $96.10M | $90.10M | — | +132.4% |
| Operating income | $279.20M | $337.80M | $190.50M | $87.50M | — | -17.3% |
| Net interest income | $18.80M | $39.30M | $41.30M | $41.00M | — | -52.2% |
| Pre-tax income | $66.10M | $447.00M | $233.90M | $151.70M | — | -85.2% |
| Tax provision | -$77.20M | $62.20M | $48.30M | $39.90M | — | -224.1% |
| Net income | $131.60M | $382.70M | $185.60M | $111.80M | — | -65.6% |
| Net income to common | $131.60M | $382.70M | $185.60M | $111.80M | — | -65.6% |
| Basic EPS | 3.91 | 11.49 | 5.66 | 3.52 | — | -66.0% |
| Diluted EPS | 3.81 | 11.15 | 5.42 | 3.31 | — | -65.8% |
| EBIT | $74.80M | $448.20M | $238.30M | $157.40M | — | -83.3% |
| EBITDA | $109.50M | $461.40M | $248.00M | $168.80M | — | -76.3% |
| Basic shares | 33.66M | 33.31M | 32.79M | 31.79M | — | +1.1% |
| Diluted shares | 34.54M | 34.32M | 34.26M | 33.75M | — | +0.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.80M | $13.30M | $8.60M | $19.40M | — | +146.6% |
| Cash & short-term investments | $369.00M | $568.20M | $532.80M | $583.30M | — | -35.1% |
| Accounts receivable | $144.50M | $215.90M | $123.00M | $149.20M | — | -33.1% |
| Total current assets | $602.60M | $837.70M | $726.50M | $752.30M | — | -28.1% |
| Property, plant & equipment | $114.80M | $53.40M | $18.60M | $26.40M | — | +115.0% |
| Goodwill & intangibles | $3.60M | $1.00M | $900.00K | $800.00K | — | +260.0% |
| Total assets | $2.66B | $2.30B | $1.77B | $1.41B | — | +15.2% |
| Total current liabilities | $23.00M | $134.00M | $109.10M | $81.00M | — | -82.8% |
| Current debt | $15.10M | — | $0 | $200.00K | $49.80M | — |
| Long-term debt | $32.80M | — | $0 | $0 | $600.00K | — |
| Total debt | $47.90M | $33.70M | $9.20M | $15.50M | — | +42.1% |
| Total liabilities | $62.10M | $242.30M | $193.20M | $138.90M | — | -74.4% |
| Retained earnings | — | $974.30M | $624.80M | $453.80M | $413.70M | — |
| Shareholder equity | $2.56B | $2.06B | $1.58B | $1.27B | — | +24.4% |
| Working capital | $579.60M | $703.70M | $617.40M | $671.30M | — | -17.6% |
| Net tangible assets | $2.56B | $2.06B | $1.57B | $1.27B | — | +24.3% |
| Shares issued | 33.90M | 33.62M | 33.29M | 32.36M | — | +0.8% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Net income | $183.90M | $410.20M | $233.90M | $134.40M | — | -55.2% |
| Depreciation & amortisation | $34.70M | $13.20M | $9.70M | $11.40M | — | +162.9% |
| Stock-based compensation | — | — | $0 | $2.70M | $15.30M | — |
| Change in working capital | -$257.60M | $28.00M | $13.80M | -$147.30M | — | -1,020.0% |
| Operating cash flow | -$21.00M | $278.60M | $131.50M | -$52.80M | — | -107.5% |
| Capital expenditure | -$102.80M | -$52.00M | -$1.90M | -$3.50M | — | -97.7% |
| Investing cash flow | $66.20M | -$260.90M | -$180.20M | $34.50M | — | +125.4% |
| Dividends paid | -$50.40M | -$33.50M | -$16.20M | -$71.70M | — | -50.4% |
| Financing cash flow | -$25.70M | -$13.00M | $37.90M | -$60.40M | — | -97.7% |
| Free cash flow | -$123.80M | $226.60M | $129.60M | -$56.30M | — | -154.6% |
| End cash position | $32.80M | $13.30M | $8.60M | $19.40M | — | +146.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $265.30M | $293.40M | $293.80M | $396.10M | $107.90M | -9.6% |
| Operating revenue | $265.30M | $293.40M | $293.80M | $396.10M | $107.90M | -9.6% |
| Cost of revenue | $215.80M | $263.80M | $191.60M | $146.90M | $68.30M | -18.2% |
| Gross profit | $49.50M | $29.60M | $102.20M | $249.20M | $39.60M | +67.2% |
| Total operating expense | $41.10M | $35.60M | $51.10M | $70.40M | $34.90M | +15.4% |
| Operating income | $8.40M | -$6.00M | $51.10M | $178.80M | $4.70M | +240.0% |
| Net interest income | $3.00M | $4.00M | $4.10M | $5.20M | $7.50M | -25.0% |
| Pre-tax income | $50.60M | -$177.20M | $25.60M | $164.60M | $6.90M | +128.6% |
| Tax provision | $27.00M | -$48.00M | $2.50M | $55.80M | -$2.40M | +156.3% |
| Net income | $34.90M | -$132.20M | $21.00M | $104.80M | $7.70M | +126.4% |
| Net income to common | $34.90M | -$132.20M | $21.00M | $104.80M | $7.70M | +126.4% |
| Basic EPS | 0.70 | -3.19 | 0.69 | 3.23 | 0.29 | +121.9% |
| Diluted EPS | 0.68 | -3.84 | 0.67 | 3.15 | 0.28 | +117.7% |
| EBIT | $54.20M | -$173.50M | $27.80M | $165.60M | $7.60M | +131.2% |
| EBITDA | $64.00M | -$163.70M | $40.10M | $170.70M | $11.70M | +139.1% |
| Basic shares | 33.94M | 41.44M | 30.43M | 32.45M | 26.55M | -18.1% |
| Diluted shares | 33.94M | 41.44M | 31.34M | 33.27M | 27.50M | -18.1% |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $32.80M | $13.30M | +146.6% |
| Cash & short-term investments | $369.00M | $568.20M | -35.1% |
| Accounts receivable | $144.50M | $215.90M | -33.1% |
| Total current assets | $602.60M | $837.70M | -28.1% |
| Property, plant & equipment | $114.80M | $53.40M | +115.0% |
| Goodwill & intangibles | $3.60M | $1.00M | +260.0% |
| Total assets | $2.66B | $2.30B | +15.2% |
| Total current liabilities | $23.00M | $134.00M | -82.8% |
| Current debt | $15.10M | — | — |
| Long-term debt | $32.80M | — | — |
| Total debt | $47.90M | $33.70M | +42.1% |
| Total liabilities | $62.10M | $242.30M | -74.4% |
| Retained earnings | — | $974.30M | — |
| Shareholder equity | $2.56B | $2.06B | +24.4% |
| Working capital | $579.60M | $703.70M | -17.6% |
| Net tangible assets | $2.56B | $2.06B | +24.3% |
| Shares issued | 33.90M | 33.62M | +0.8% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders53.74%
Held by institutions6.35%
Institutions holding3
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
283.19
-1.69% from price
SMA 20
283.47
-1.86% from price
SMA 50
284.47
-2.20% from price
SMA 100
283.94
-1.95% from price
SMA 200
284.17
-2.10% from price
EMA 12
281.64
-1.15% from price
EMA 26
282.59
-1.48% from price
EMA 50
283.02
-1.63% from price
RSI (14)
45.5
Neutral
MACD (12,26,9)
-0.96
Hist -1.32
ATR (14)
10.24
3.68% of price
Realised vol 30D
27.2%
Annualised
Bollinger upper
299.28
20, 2σ
Bollinger lower
267.67
20, 2σ
50 / 200 cross
Golden
284.47 vs 284.17
Trend bias
Below 200
-2.10%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.24
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
27.2%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-19.3%
Peak to trough
Max drawdown 5Y
-41.7%
Peak to trough
ATR 14
10.24
3.68% of price
Beta (reported)
0.21
5Y monthly, from filing
Dividends & splits
Forward rate$1.50 / yr
Forward yield0.50%
5-year avg yield1.53%
Payout ratio0.00%
Ex-dividend dateJun 26, 2025
Next pay date—
Last split—
Split date—
Headlines
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
Clinical Trials Arena · 2m ago
Morning Bid: Economic salvos
Reuters · 3m ago
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Hospital Management · 7m ago
SealingTech, a Parsons Corporation company, receives $750 Million Joint Cyber Hunt Kit (JCHK) Full-Rate Production Award from USCYBERCOM
PR Newswire · 9m ago
One in Three U.S. Women Are Already Using AI for Skincare and Bodycare Advice, New Survey Finds
PR Newswire · 9m ago
Innovent Announces 2026 Interim Results and Business Updates
PR Newswire · 9m ago
RBC creates unified Global Transaction Banking business, combining strengths across leading businesses
PR Newswire · 9m ago
Student Storytellers at Boys & Girls Clubs of Twin Cities Take Center Stage at Dream to Screen Awards Powered by Epson, with Special Appearance by Epson Ambassador Shaquille O'Neal
PR Newswire · 9m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.